Ergomed plc Board changes (4305Z)

TIDMERGO

RNS Number : 4305Z

Ergomed plc

15 December 2017

PRESS RELEASE

Board changes

Stephen Stamp appointed as CEO and Jan Petracek as COO

London, UK - 15 December 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, today announces changes to its Board and management team with the appointment of Stephen Stamp as Chief Executive Officer and Dr Jan Petracek as Chief Operating Officer and a Board Director of Ergomed with immediate effect. Dr Dan Weng has decided to step down as CEO with immediate effect.

Stephen Stamp has been Ergomed's Chief Financial Officer, and member of the Board of Directors, since January 2016. Prior to this, he had spent more than 30 years in corporate finance and general management in both public and private companies in the UK and the USA. He has held senior roles at a number of healthcare businesses in the UK and US and, as CFO, led the IPO of Shire on the London Stock Exchange and NASDAQ as well as a number of major acquisitions. A search for a new CFO will be undertaken.

Dr Jan Petracek has been CEO of Ergomed's pharmacovigilance subsidiary PrimeVigilance, since April 2017, having joined the Company in November 2016 following the acquisition of European PharmInvent Services s.r.o. where he was CEO. Dr Petracek is the former Head of Risk Management Section at the European Medicines Agency, and the former Head of Pharmacovigilance, Strategy and Development at the State Institute for Drug Control in the Czech Republic.

Peter George, Chairman of Ergomed, said: "Stephen has exceptionally wide business experience and has developed a deep understanding of Ergomed and its markets. His move to CEO makes strong strategic sense as the Company looks to continue to deliver on its strategy. I am also delighted to have Jan join the Board as COO. He has added significant value to the executive management team since joining Ergomed in 2016 and his vision and drive has contributed substantially to our pharmacovigilance business which continues to significantly outpace the growth of a fast growing market. We look forward to his contribution across our wider services business and the Company as a whole.

"I'd like to thank Dan for his contributions this year and wish him well with his future endeavours."

Dr Jan Petracek, aged 42, currently holds the following directorships and has held no other directorships in the past five years:

 
 Current directorships:   European Pharminvent Services s.r.o. 
                           Pharminvent regulatory s.r.o. 
                           PrimeVigilance d.o.o. Beograd-Novi 
                           Beograd 
                           PrimeVigilance Inc. 
                           PRIMEVIGILANCE LIMITED 
                           PrimeVigilance Zagreb d.o.o. 
                           SOUND OPINION LIMITED 
 

Dr Jan Petracek holds 367,597 Ordinary Shares of 1 penny each in the Company.

Ergomed confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Dr Petracek's appointment.

ENDS

Enquiries:

 
 Ergomed plc                                           Tel: +44 (0) 
                                                        1483 503205 
 Peter George (Chairman) 
 Stephen Stamp (Chief Executive 
  Officer) 
 
 Numis Securities Limited                              Tel: +44 (0) 
                                                       20 7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
 James Black (Joint Broker) 
 
 N+1 Singer                                            Tel: +44 (0) 
                                                       20 7496 3000 
 Alex Price (Joint Broker) 
 
 Consilium Strategic Communications                    Tel: +44 (0) 
  - for UK enquiries                                   20 3709 5700 
 Chris Gardner / Mary-Jane              [e-mail] 
  Elliott 
  Ivar Milligan / Philippa Gardner 
 
 MC Services - for Continental                         Tel: +49 211 
  European enquiries                                      5292 5222 
 Anne Hennecke 
 
 

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOALLFVDFDLSLID

(END) Dow Jones Newswires

December 15, 2017 02:00 ET (07:00 GMT)